The story · written by gpt-6,
Cyprus announced a restricted cannabis-oil programme for patients with advanced cancer in January 2017. Health Minister George Pamboridis said it would cover people for whom other treatments had proved ineffective, with applications made directly to the ministry.
Patients needed a decision on their own case
The announcement described oil being provided free through the ministry after approval. Authorities were looking abroad for supply because a domestic medical-growing system had yet to be introduced.
The change addressed patients already facing advanced illness and limited treatment options. It brought a controlled medical exception into a system that otherwise criminalised unauthorised cannabis possession and use.
Pamboridis also announced work on wider legislation. That opened a second question alongside immediate patient access: how Cyprus would regulate the production and supply of medical cannabis.
The doctor prescribed and the minister approved
In July, ministry press officer Margarita Kyriakou explained the process publicly. A patient submitted a request with their treating doctor’s report. The minister could approve an individual exception and notify Pharmaceutical Services.
The patient still needed a doctor’s prescription. Pharmaceutical Services then identified the chemist from which the approved oil could be obtained.
This divided responsibility between clinical prescribing, ministerial authorisation and the pharmacy supply arrangements. Each patient’s permission was tied to their own treatment.
Ordinary possession and use remained criminal offences
The underlying drug law continued to prohibit unauthorised cannabis acquisition, possession, cultivation and supply. Its medical exceptions depended on the relevant authorisation and regulatory conditions.
That distinction was important for patients: the announced programme offered a route through the health authorities, while cannabis bought outside that route remained subject to the ordinary law.
The government’s existing power to authorise otherwise prohibited activities supplied the legal setting for individual treatment decisions. Wider production and prescribing rules would later give the medical system more detailed requirements.
Production rules and imported oils followed
In March 2019, Cyprus published regulations for licensed medical producers, quality controls, pharmacy preparations and prescriptions. They included separate approval arrangements for patients under eighteen.
A government purchase of imported oils was documented in 2021, when Panaxia secured an order and subsequently announced its first delivery to Cyprus.
The country profile follows this progression from restricted patient approval to a broader regulatory framework and a documented supply shipment, while keeping recreational access separate from the medical route.[1][2][3][4][5]
Score by segment 0 to 10
- Possession · 25%1 → 1
- Personal cultivation · 25%0 → 0
- Punishment & enforcement · 20%1 → 1
- Sharing & gifting · 10%0 → 0
- Consumption · 10%0 → 0
- Legal access · 10%0 → 1+1
The bar shows the score after the change; the tick marks where it stood before. The scores after the change are Cyprus's current scores.
References
- TalkingDrugs — Cyprus set to provide cannabis oil to cancer patients, 1 February 2017Avinash Tharoor reports late-January announcement by George Pamboridis: advanced cancer, ineffective other treatments, applications to ministry, intended free oil and imported supplyarchived
- Cyprus Health Ministry press officer Margarita Kyriakou — explanation of cannabis-oil access, 23 July 2017Signed ministry statement published in Cyprus Mail: named-patient request and medical report, ministerial exception, doctor’s prescription, Pharmaceutical Services and designated chemistarchived
- Cyprus — Narcotic Drugs and Psychotropic Substances Law, consolidated text, CyLawSections 2, 5–8, 10, 30 and 30A; schedules 1 and 3; amendments listed through 159(I)/2020; two-year young first-offender cap and rebuttable supply presumptionsarchived
- Cyprus Health Ministry — original medical-cannabis regulations, 6 March 2019KDP 73/2019; regulations 3–7, 17–24 and 94–95; visually checked printed pp. 378, 381, 385, 387, 389 and 414; three-producer opening, fifteen-year protection, adult prescribing and separate approval for minorsarchived
- Jerusalem Post — Panaxia announces first delivery to Cyprus, 26 March 2021Reports company announcement on Thursday 25 March, following Israeli ministry/customs checks; products sold to government for pharmacy distribution; first Panaxia delivery, not first-ever cannabis importarchived
Checked. The date and the event were compared with a source that was read. The score before the change is an editorial estimate.